{"id":"melitracen","rwe":[{"pmid":"40827342","year":"2025","title":"A Cross-Sectional Study on the Drug Use of Insomnia in a Chinese Medicine Hospital in Shenzhen.","finding":"","journal":"Psychiatry and clinical psychopharmacology","studyType":"Clinical Study"},{"pmid":"40808745","year":"2025","title":"Efficacy and safety of flupentixol-melitracen in patients with refractory chronic cough: a randomised, double-blinded, placebo-controlled clinical trial.","finding":"","journal":"EClinicalMedicine","studyType":"Clinical Study"},{"pmid":"40735004","year":"2025","title":"Therapeutic Efficacy of Flupentixol-Melitracen for Treatment of Aerophagia in Adults: A Single-Center Parallel Randomized Controlled Trial.","finding":"","journal":"JGH open : an open access journal of gastroenterology and hepatology","studyType":"Clinical Study"},{"pmid":"40653504","year":"2025","title":"Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain-bladder axis.","finding":"","journal":"Scientific reports","studyType":"Clinical Study"},{"pmid":"40580713","year":"2025","title":"Fate of antidepressants in municipal wastewater: Activated carbon as the most effective removal strategy for amitriptyline, melitracen, and their transformation products.","finding":"","journal":"The Science of the total environment","studyType":"Clinical Study"}],"tags":[{"label":"Tricyclic Antidepressants","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N06AA14","category":"atc"},{"label":"Active","category":"status"},{"label":"Antidepressive Agents","category":"pharmacology"},{"label":"Antidepressive Agents, Tricyclic","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"dixeran","offLabel":[],"synonyms":["melitracen hydrochloride","dixeran","melitracen","melitracene","melitracen HCl"],"timeline":[],"approvals":[],"brandName":"Dixeran","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Tricyclic Antidepressants","explanation":"Imagine your brain is a city with many messengers running around, delivering important messages. Dixeran helps keep these messengers, called neurotransmitters, in the city longer, so they can do their job more effectively. This can help improve mood and reduce symptoms of depression.","oneSentence":"Dixeran works by inhibiting the reuptake of certain neurotransmitters, such as serotonin and norepinephrine, in the brain.","technicalDetail":"Dixeran acts as a selective inhibitor of the serotonin and norepinephrine reuptake transporters (SERT and NET), increasing the concentration of these neurotransmitters in the synaptic cleft and enhancing their activity."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Melitracen","title":"Melitracen","extract":"Melitracen is a tricyclic antidepressant (TCA), for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, marketed by Lundbeck, a combination product containing both melitracen and flupentixol."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1675","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MELITRACEN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MELITRACEN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Melitracen","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T14:18:11.376497","biosimilars":[],"competitors":[{"drugName":"desipramine","drugSlug":"desipramine","fdaApproval":"1964-11-20","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"imipramine","drugSlug":"imipramine","fdaApproval":"1959-04-16","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clomipramine","drugSlug":"clomipramine","fdaApproval":"1989-12-29","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"trimipramine","drugSlug":"trimipramine","fdaApproval":"1979-06-12","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nortriptyline","drugSlug":"nortriptyline","fdaApproval":"1964-11-06","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"protriptyline","drugSlug":"protriptyline","fdaApproval":"1967-09-27","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"doxepin","drugSlug":"doxepin","fdaApproval":"1969-09-23","patentExpiry":"Sep 7, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"maprotiline","drugSlug":"maprotiline","fdaApproval":"1980-12-01","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"melitracen","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"desipramine","brandName":"desipramine","genericName":"desipramine","approvalYear":"1964","relationship":"same-class"},{"drugId":"imipramine","brandName":"imipramine","genericName":"imipramine","approvalYear":"1959","relationship":"same-class"},{"drugId":"clomipramine","brandName":"clomipramine","genericName":"clomipramine","approvalYear":"1989","relationship":"same-class"},{"drugId":"trimipramine","brandName":"trimipramine","genericName":"trimipramine","approvalYear":"1979","relationship":"same-class"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-class"},{"drugId":"nortriptyline","brandName":"nortriptyline","genericName":"nortriptyline","approvalYear":"1964","relationship":"same-class"},{"drugId":"protriptyline","brandName":"protriptyline","genericName":"protriptyline","approvalYear":"1967","relationship":"same-class"},{"drugId":"doxepin","brandName":"doxepin","genericName":"doxepin","approvalYear":"1969","relationship":"same-class"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-class"},{"drugId":"maprotiline","brandName":"maprotiline","genericName":"maprotiline","approvalYear":"1980","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06945237","phase":"NA","title":"Efficacy of Gut-Brain Neuromodulators in the Treatment of Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2025-04-24","conditions":["Gastroesophageal Reflux Disease"],"enrollment":164,"completionDate":"2025-10-30"},{"nctId":"NCT03513185","phase":"","title":"Assessment of SSD in Outpatients Using SSS-CN","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2017-09-01","conditions":["Somatization Disorder"],"enrollment":1863,"completionDate":"2021-12-30"},{"nctId":"NCT06756139","phase":"NA","title":"Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia","status":"RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-11-01","conditions":["Functional Dyspepsia","Self-help Mobile Cognitive Behavioral Therapy","Antipsychotic Drug"],"enrollment":88,"completionDate":"2025-11-01"},{"nctId":"NCT06931223","phase":"NA","title":"Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-10","conditions":["Functioanl Dyspepsia"],"enrollment":200,"completionDate":"2025-09-10"},{"nctId":"NCT06927375","phase":"PHASE4","title":"A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2024-12-12","conditions":["Thyroid-Associated Ophthalmopathy"],"enrollment":60,"completionDate":"2026-03-12"},{"nctId":"NCT03472651","phase":"PHASE1","title":"Bioequivalence Study to Compare Two Formulations of Deanxit®","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-05-07","conditions":["Healthy"],"enrollment":60,"completionDate":"2018-06-28"},{"nctId":"NCT05099913","phase":"NA","title":"The Role of Neuromodulators in Refractory Functional Dyspepsia","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2020-08-01","conditions":["Dyspepsia","Functional Gastrointestinal Disorders","Antidepressant Discontinuation Syndrome","Antidepressant Drug Adverse Reaction"],"enrollment":220,"completionDate":"2022-12-30"},{"nctId":"NCT04970667","phase":"PHASE4","title":"Flupentixol and Melitracen Tablets in the Treatment of Emotional Disorder","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2018-01-01","conditions":["Emotional Disorder","Neurologic Disorder"],"enrollment":100,"completionDate":"2020-04-30"},{"nctId":"NCT02723903","phase":"PHASE1,PHASE2","title":"Hierarchical Treatment Based on Somatization Symptom Checklist","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2015-12","conditions":["Syndrome X"],"enrollment":200,"completionDate":"2021-12"},{"nctId":"NCT03600974","phase":"","title":"A New System for GERD Diagnosis and Treatment","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2019-02-01","conditions":["GERD"],"enrollment":200,"completionDate":"2021-07-01"},{"nctId":"NCT03205228","phase":"PHASE3","title":"Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-07","conditions":["Globus"],"enrollment":40,"completionDate":"2018-07-28"},{"nctId":"NCT01851863","phase":"PHASE4","title":"Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2013-05","conditions":["Dyspepsia","Compliance","Depression"],"enrollment":262,"completionDate":"2014-06"},{"nctId":"NCT02179931","phase":"PHASE1","title":"Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-06","conditions":["Healthy Men and Women"],"enrollment":30,"completionDate":""},{"nctId":"NCT00841230","phase":"PHASE4","title":"Deanxit and Rivotril in Tinnitus Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2009-02","conditions":["Tinnitus"],"enrollment":50,"completionDate":"2009-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"009772","UNII":"Q7T0Y1109Z","CHEBI":"CHEBI:31815","INN_ID":"1568","RXNORM":"446248","UMLSCUI":"C1377670","ChEMBL_ID":"CHEMBL110094","KEGG_DRUG":"D01110","DRUGBANK_ID":"DB13384","PUBCHEM_CID":"25382","SNOMEDCT_US":"712683007","SECONDARY_CAS_RN":"10563-70-9","MESH_SUPPLEMENTAL_RECORD_UI":"C005100"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":102,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N06AA14","allCodes":["N06AA14","N06CA02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Jul 28","pmid":"40827342","title":"A Cross-Sectional Study on the Drug Use of Insomnia in a Chinese Medicine Hospital in Shenzhen.","journal":"Psychiatry and clinical psychopharmacology"},{"date":"2025 Aug","pmid":"40808745","title":"Efficacy and safety of flupentixol-melitracen in patients with refractory chronic cough: a randomised, double-blinded, placebo-controlled clinical trial.","journal":"EClinicalMedicine"},{"date":"2025 Aug","pmid":"40735004","title":"Therapeutic Efficacy of Flupentixol-Melitracen for Treatment of Aerophagia in Adults: A Single-Center Parallel Randomized Controlled Trial.","journal":"JGH open : an open access journal of gastroenterology and hepatology"},{"date":"2025 Jul 13","pmid":"40653504","title":"Flupentixol/melitracen for epigastric pain syndrome in female patients with abnormal urinalysis and therapeutic insights into the brain-bladder axis.","journal":"Scientific reports"},{"date":"2025 Aug 25","pmid":"40580713","title":"Fate of antidepressants in municipal wastewater: Activated carbon as the most effective removal strategy for amitriptyline, melitracen, and their transformation products.","journal":"The Science of the total environment"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dixeran, also known as MELITRACEN, is a small molecule Tricyclic Antidepressant. Its original developer and current owner are unknown. It is used to treat various conditions, but its exact target and approved indications are not specified. The commercial status of Dixeran is unclear, and it is not known whether it is patented or available as a generic medication. Further information on its pharmacokinetics and safety profile is also lacking.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}